Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients : the SOLID study
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria)
Ortega Granados, Ana Laura (Hospital Universitario de Jaén)
Serrano, Gloria (Hospital Universiario Infanta Leonor (Madrid))
Aguado, Carlos (Hospital Clínico San Carlos (Madrid))
Franco, Fernando (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Gutierrez, Vanesa (Hospital Universitario Regional de Málaga)
López-Vivanco, Guillermo (Hospital Universitario Cruces (Barakaldo, País Basc))
Guirado Risueño, María (Hospital General Universitario de Elche)
Benítez, Gretel (Hospital Universitario Insular de Gran Canaria)
Estival, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda)
Jiménez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid))
Arasanz, Hugo (Complejo Hospitalario Navarra-Navarrabiomeed)
Coves, Juan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Massutí, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià))
Vázquez, Sergio (Hospital Universitario Lucus Augusti (Lugo))
Juan, Óscar (Hospital Universitario y Politécnico La Fe)
Collazo-Lorduy, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Gozálvez, Clara L. (Hospital Universitari Sant Joan de Reus (Tarragona))
Barco, Edel D. (Hospital Clínico Universitario (Salamanca))
Rosero, Adriana (Hospital Universitario Infanta Cristina)
Bosch-Barrera, J. (Institut Català d'Oncologia)
Moreno, María A. (Hospital Universitario de Puerto Real (Cadis))
Mielgo-Rubio, X. (Hospital Universitario Fundación Alcorcón)
Villa, J.C. (Hospital General Universitario Ciudad Real)
López-Martin, A. (Hospital Universitario Severo Ochoa)
Córdoba Ortega, Juan Felipe (Hospital Universitario Arnau de Vilanova)
de Asís Aparisi, F. (Hospital General Universitario de Valencia)
Zafra, M. (Hospital General Universitario Morales Meseguer (Múrcia))
Mosquera, J. (Complejo Hospitalario Universitario de A Coruña)
Altozano, J.P. (Hospital Virgen de los Lirios)
Nadal, E. (Institut Català d'Oncologia. Hospitalet de Llobregat)
Catot, S. (Altaia. Xarxa Assistencial Universitaria Manresa)
Balsalobre, J. (Hospital General Universitario Santa Lucia Cartagena)
de Portugal, T. (Complejo Hospitalario de Zamora)
Martín, P. (Hospital Clínic Universitari (València))
de Juan, S.C. (Laboratorio Central)
Cobo, M. (Hospital Universitario Regional de Málaga)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Of 1,500 patients, 128 were seropositive, overall prevalence of 8. 5% seropositivity [95% confidence interval (CI): 7. 2-10. 1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38. 8-56. 6%). A second determination was performed on average 4. 5 months later [interquartile range (IQR), 4. 0-5. 0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30. 8% of patients. The severity of the infection, the need for hospitalization (P=0. 032) and the presence of symptoms at diagnosis (P=0. 02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. ClinicalTrials. gov identifier: NCT04407143.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Immunity ; Lung cancer ; Seroprevalence ; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Publicado en:	Translational Lung Cancer Research, Vol. 11 Núm. 1 (january 2022) , p. 53-63, ISSN 2226-4477

DOI: 10.21037/tlcr-21-504
PMID: 35242627

11 p, 639.3 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados